What Insurance Does a Life Sciences Company Need for a Clinical Trial Outside the US?

A clinical trial run outside the United States is not a US trial with a foreign address. It is a regulated activity under another jurisdiction’s framework, with its own consent rules, sponsor obligations, and indemnification expectations baked into the agreement with the foreign site. A US clinical trial liability policy does not automatically extend to international sites, and a sponsor that assumes it does discovers the gap the moment a subject in Berlin or Sao Paulo brings a claim and the local court asks who carries cover that responds there.

The Host Country Sets the Terms

Every jurisdiction that hosts clinical research applies its own rules to the trial, layered on top of the international ICH-GCP guidelines that act as the common reference. The EU Clinical Trials Regulation, the UK Medicines for Human Use Regulations, Health Canada’s framework, Japan’s Pharmaceuticals and Medical Devices Act, and Australia’s CTN scheme all require evidence of insurance as part of trial authorization, and several require local admitted coverage rather than accepting a US policy by itself. The specific limits, the specific exhibits, and the specific endorsements expected vary by country, and the country competent authority, not the sponsor, decides what counts.

The reason is not bureaucratic. It is that a subject injured in the trial is a foreign citizen with rights under foreign law, and the local regulator wants confidence the sponsor’s coverage will respond in that forum. A US clinical trial liability policy written for US sites, US IRBs, and US courts often does not meet that standard, regardless of how broad it is at home.

What Has to Be in the Program

International trial coverage is built from three layers. The first is sponsor-side clinical trial liability with explicit international territory, or a parallel local trial policy in each host country, sized to the protocol’s subject count, indication risk, and follow-up period. The second is products liability for the investigational device or drug, extended to the foreign jurisdictions where the trial runs, because the investigational article is the source of any harm-from-the-product claim. The third is the contractual layer: the agreement with the foreign site usually carries indemnification flowing from sponsor to site, and the sponsor’s policy has to back that indemnity in the local jurisdiction, not just on paper.

The CRO dimension multiplies all three. A CRO running an international trial on the sponsor’s behalf carries its own coverage obligations, and the master services agreement’s reciprocal additional insured and limit requirements must match the local market in each country, the same structural issue mapped in clinical trial insurance for sponsors and CROs. A US-only CRO program meeting US contract terms can fail in a host country with stricter local requirements.

The Seams That Most Often Open

Three seams produce the most claims-side surprises in international trials. The first is the territory wording on the sponsor’s CTL: a policy with worldwide territory but US-court-only coverage is not a full answer, and the foreign-court question has to be read directly. The second is the local admitted-coverage requirement: some host countries do not accept non-admitted insurance for trial liability, so a parallel local policy has to be placed even when the master CTL nominally reaches the country. The third is the seam between the trial and the commercial product on the other side of clearance, which is hard enough domestically and harder across borders, the dynamic mapped in how a clinical trial reshapes the device insurance program and in what changes about insurance at FDA clearance for the US side.

A difference in conditions program over the local policies can harmonize coverage across a multi-country trial when the local forms vary significantly, the structure described in what difference in conditions insurance is for a life sciences company. Whether DIC, a worldwide CTL, or a portfolio of local policies fits depends on the trial’s geography and the variation in local requirements.

What to Do Before the Foreign Site Opens

Treat trial start-up the way you treat protocol authorization. Before the first subject is consented in any foreign country, confirm with your broker that the CTL program meets that country’s authorization requirements, that the products liability extends to investigational use in that jurisdiction, and that the site agreement’s indemnification language is backed by the policies on both sides. Read the foreign country’s specific coverage exhibits, not a generic list. If a local admitted policy is required, place it before the authorization submission, not after.

A foreign trial that opens without that work is not running uninsured; it is running on a US policy that was not asked the foreign question, which is the same outcome from a different direction. A specialty review through Tower Street Insurance can structure international trial coverage by country, coordinated with the sponsor’s commercial program and the foreign site agreements, before the protocol submission goes in.